GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
If the drug manufacturer can meet this demand, then the drug is not in shortage
Liraglutide is another popular medication prescribed for weight loss
Promotes Exercise Recovery: Aids in quicker recovery post-exercise by boosting natural energy levels
Starting at $189 per month, PlexusDx semaglutide is available without insurance or membership fees, and it qualifies for HSA and FSA accounts
Pregnancy registry:There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound (tirzepatide) during pregnancy